随着对病毒感染的易感性相应增加,这些感染中有相当一部分可以通过预防措施或适当的治疗干预得到有效纠正。 CAR-T细胞输注(CAR-T-cell infusion,CTI)前 在CTI前,感染风险增加与基础血液恶性肿瘤相互交织。多线治疗也是导致恶性肿瘤感染易感性...
[6] Tan X, Wang X Q, Zhang C, et al. Donor-derived CD19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD19-positive B-ALL After Allogeneic Hematopoietic Stem Cell Transpl...
The antigen-loaded nanogel may be administered prior to administration of antigen-specific T cells to improve the efficacy of a T cell infusion therapy against an immune checkpoint inhibitor-resistant tumor. The hydrophobized polysaccharide may be pullulan having cholesteryl groups bound thereto. An ...
CAR-T细胞疗法（Chimeric Antigen Receptor T-Cell Therapy）是一种创新的细胞治疗方法，通过基因工程技术改造患者自身的T细胞，使其具备识别和杀伤特定癌细胞或病变细胞的能力。这种疗法在治疗某些类型的血液癌症（如白血病和淋巴瘤）中取得了显著效果。治疗过程：采集T细胞： 从患者的血液中提取T细胞，通常通过血液分离技术...
[7]Pan K, Li YQ, Wang W, et al. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol. 2013;20(13):4305-4311. https://pubmed.ncbi.nlm.nih.gov/23892527/ ...
et al. Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy. Cancer Immunol. Res. 8, 926–936 (2020). CAS PubMed Google Scholar Cruz, C. R. et al. Infusion of donor-derived CD19-redirected virus-...
[7]Pan K, Li YQ, Wang W, et al. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol. 2013;20(13):4305-4311. https://pubmed.ncbi.nlm.nih.gov/23892527/ ...
嵌合抗原受体(CAR)和T细胞受体(TCR)修饰的T细胞是当前过继性细胞治疗技术(Adoptive Cellular Therapy,ACT)中两大核心技术,通过工程化编辑使得T细胞表达人工合成受体并具有特异性识别靶细胞的能力,可实现对血液相关肿瘤(如白血病和淋巴瘤)的长期缓解甚至治愈,正在彻底改变癌症的治疗方法。
[1]Good, Z., Spiegel, J.Y., Sahaf, B. et al. Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy. Nat Med (2022). https://doi.org/10.1038/s41591-022-01960-7 [2]Haradhvala, N.J., Leick, M.B., Maurer, K. et al. Distinct cellular dynamics associated...
2. FDA approval brings first gene therapy to theUnited States.3.Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.N Engl J Med 2017 4. Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T ...